126 related articles for article (PubMed ID: 27637077)
1. SIRT2 deletion enhances KRAS-induced tumorigenesis in vivo by regulating K147 acetylation status.
Song HY; Biancucci M; Kang HJ; O'Callaghan C; Park SH; Principe DR; Jiang H; Yan Y; Satchell KF; Raparia K; Gius D; Vassilopoulos A
Oncotarget; 2016 Dec; 7(49):80336-80349. PubMed ID: 27637077
[TBL] [Abstract][Full Text] [Related]
2. FOSL1 Promotes Kras-induced Lung Cancer through Amphiregulin and Cell Survival Gene Regulation.
Elangovan IM; Vaz M; Tamatam CR; Potteti HR; Reddy NM; Reddy SP
Am J Respir Cell Mol Biol; 2018 May; 58(5):625-635. PubMed ID: 29112457
[TBL] [Abstract][Full Text] [Related]
3. Loss of Sirt2 increases and prolongs a caerulein-induced pancreatitis permissive phenotype and induces spontaneous oncogenic Kras mutations in mice.
Quan S; Principe DR; Dean AE; Park SH; Grippo PJ; Gius D; Horikoshi N
Sci Rep; 2018 Nov; 8(1):16501. PubMed ID: 30405152
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer.
Shin DH; Jo JY; Choi M; Kim KH; Bae YK; Kim SS
Exp Mol Med; 2023 Oct; 55(10):2220-2237. PubMed ID: 37779142
[TBL] [Abstract][Full Text] [Related]
5. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer.
Vallejo A; Perurena N; Guruceaga E; Mazur PK; Martinez-Canarias S; Zandueta C; Valencia K; Arricibita A; Gwinn D; Sayles LC; Chuang CH; Guembe L; Bailey P; Chang DK; Biankin A; Ponz-Sarvise M; Andersen JB; Khatri P; Bozec A; Sweet-Cordero EA; Sage J; Lecanda F; Vicent S
Nat Commun; 2017 Feb; 8():14294. PubMed ID: 28220783
[TBL] [Abstract][Full Text] [Related]
6. In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer.
Grzeskowiak CL; Kundu ST; Mo X; Ivanov AA; Zagorodna O; Lu H; Chapple RH; Tsang YH; Moreno D; Mosqueda M; Eterovic K; Fradette JJ; Ahmad S; Chen F; Chong Z; Chen K; Creighton CJ; Fu H; Mills GB; Gibbons DL; Scott KL
Nat Commun; 2018 Jul; 9(1):2732. PubMed ID: 30013058
[TBL] [Abstract][Full Text] [Related]
7. Insulin receptor substrate-1 deficiency drives a proinflammatory phenotype in KRAS mutant lung adenocarcinoma.
Metz HE; Kargl J; Busch SE; Kim KH; Kurland BF; Abberbock SR; Randolph-Habecker J; Knoblaugh SE; Kolls JK; White MF; Houghton AM
Proc Natl Acad Sci U S A; 2016 Aug; 113(31):8795-800. PubMed ID: 27439864
[TBL] [Abstract][Full Text] [Related]
8. IKKβ Kinase Promotes Stemness, Migration, and Invasion in KRAS-Driven Lung Adenocarcinoma Cells.
Rodrigues FS; Miranda VS; Carneiro-Lobo TC; Scalabrini LC; Kruspig B; Levantini E; Murphy DJ; Bassères DS
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823550
[TBL] [Abstract][Full Text] [Related]
9. Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung Cancer.
Mustachio LM; Lu Y; Tafe LJ; Memoli V; Rodriguez-Canales J; Mino B; Villalobos PA; Wistuba I; Katayama H; Hanash SM; Roszik J; Kawakami M; Cho KJ; Hancock JF; Chinyengetere F; Hu S; Liu X; Freemantle SJ; Dmitrovsky E
Mol Cancer Res; 2017 Jul; 15(7):905-914. PubMed ID: 28242811
[No Abstract] [Full Text] [Related]
10. Oncogenic KRASG12D Reprograms Lipid Metabolism by Upregulating SLC25A1 to Drive Pancreatic Tumorigenesis.
Zhang R; Peng X; Du JX; Boohaker R; Estevao IL; Grajeda BI; Cox MB; Almeida IC; Lu W
Cancer Res; 2023 Nov; 83(22):3739-3752. PubMed ID: 37695315
[TBL] [Abstract][Full Text] [Related]
11. UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinoma.
Kostyrko K; Román M; Lee AG; Simpson DR; Dinh PT; Leung SG; Marini KD; Kelly MR; Broyde J; Califano A; Jackson PK; Sweet-Cordero EA
Nat Commun; 2023 Jul; 14(1):3966. PubMed ID: 37407562
[TBL] [Abstract][Full Text] [Related]
12. Activation of KrasG12D in Subset of Alveolar Type II Cells Enhances Cellular Plasticity in Lung Adenocarcinoma.
Chaudhary P; Xu X; Wang G; Hoj JP; Rampersad RR; Asselin-Labat ML; Ting S; Kim W; Tamayo P; Pendergast AM; Onaitis MW
Cancer Res Commun; 2023 Nov; 3(11):2400-2411. PubMed ID: 37882674
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of SAG/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis.
Li H; Tan M; Jia L; Wei D; Zhao Y; Chen G; Xu J; Zhao L; Thomas D; Beer DG; Sun Y
J Clin Invest; 2014 Feb; 124(2):835-46. PubMed ID: 24430184
[TBL] [Abstract][Full Text] [Related]
14. p53 dosage can impede KrasG12D- and KrasQ61R-mediated tumorigenesis.
Le Roux Ö; Everitt JI; Counter CM
PLoS One; 2024; 19(3):e0292189. PubMed ID: 38547169
[TBL] [Abstract][Full Text] [Related]
15. Loss of adipose triglyceride lipase is associated with human cancer and induces mouse pulmonary neoplasia.
Al-Zoughbi W; Pichler M; Gorkiewicz G; Guertl-Lackner B; Haybaeck J; Jahn SW; Lackner C; Liegl-Atzwanger B; Popper H; Schauer S; Nusshold E; Kindt AS; Trajanoski Z; Speicher MR; Haemmerle G; Zimmermann R; Zechner R; Vesely PW; Hoefler G
Oncotarget; 2016 Jun; 7(23):33832-40. PubMed ID: 27213586
[TBL] [Abstract][Full Text] [Related]
16. Silencing KRAS Overexpression in Cadmium-Transformed Prostate Epithelial Cells Mitigates Malignant Phenotype.
Ngalame NN; Waalkes MP; Tokar EJ
Chem Res Toxicol; 2016 Sep; 29(9):1458-67. PubMed ID: 27510461
[TBL] [Abstract][Full Text] [Related]
17. HDAC10 Regulates Cancer Stem-Like Cell Properties in KRAS-Driven Lung Adenocarcinoma.
Li Y; Zhang X; Zhu S; Dejene EA; Peng W; Sepulveda A; Seto E
Cancer Res; 2020 Aug; 80(16):3265-3278. PubMed ID: 32540961
[TBL] [Abstract][Full Text] [Related]
18. Oxidative stress activates SIRT2 to deacetylate and stimulate phosphoglycerate mutase.
Xu Y; Li F; Lv L; Li T; Zhou X; Deng CX; Guan KL; Lei QY; Xiong Y
Cancer Res; 2014 Jul; 74(13):3630-42. PubMed ID: 24786789
[TBL] [Abstract][Full Text] [Related]
19. SIRT2-mediated inactivation of p73 is required for glioblastoma tumorigenicity.
Funato K; Hayashi T; Echizen K; Negishi L; Shimizu N; Koyama-Nasu R; Nasu-Nishimura Y; Morishita Y; Tabar V; Todo T; Ino Y; Mukasa A; Saito N; Akiyama T
EMBO Rep; 2018 Nov; 19(11):. PubMed ID: 30213795
[TBL] [Abstract][Full Text] [Related]
20. The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas.
Valencia K; Erice O; Kostyrko K; Hausmann S; Guruceaga E; Tathireddy A; Flores NM; Sayles LC; Lee AG; Fragoso R; Sun TQ; Vallejo A; Roman M; Entrialgo-Cadierno R; Migueliz I; Razquin N; Fortes P; Lecanda F; Lu J; Ponz-Sarvise M; Chen CZ; Mazur PK; Sweet-Cordero EA; Vicent S
J Clin Invest; 2020 Apr; 130(4):1879-1895. PubMed ID: 31874105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
